Financial Performance - Total revenues for the three months ended June 30, 2024, were $797,519, a decrease of 72.7% compared to $2,917,341 for the same period in 2023[11]. - Product revenues for the three months ended June 30, 2024, were $246,644, down 22.1% from $316,950 in the prior year[11]. - Clinical laboratory service revenues for the three months ended June 30, 2024, were $324,730, a significant decline from $2,174,697 in the same quarter of 2023[11]. - Gross profit for the three months ended June 30, 2024, was $245,232, compared to $1,269,318 for the same period in 2023, reflecting a decrease of 80.7%[11]. - Total revenue for the nine-month period ended June 30, 2024, was $2,618,313, down 79.2% from $12,587,707 for the same period in 2023[37]. - Gross profit for the nine-month period ended June 30, 2024, was $771,980, significantly lower than $5,454,436 in the same period of 2023[100][103]. - The loss from segment operations for the nine-month period ended June 30, 2024, was $(6,748,159), compared to $(3,395,005) in the same period of 2023, indicating a worsening of approximately 98.1%[100][103]. Expenses and Losses - Operating expenses for the three months ended June 30, 2024, totaled $3,591,925, a decrease of 12.9% from $4,128,427 in the same quarter of 2023[11]. - The company reported a net loss attributable to Applied DNA Sciences, Inc. for the three months ended June 30, 2024, was $1,879,796, compared to a net loss of $(3,099,766) in the same period of 2023[11]. - For the nine-month period ended June 30, 2024, the net loss was $3,774,563, compared to a net loss of $6,407,265 for the same period in 2023, indicating a 41% improvement in losses year-over-year[19]. - The company incurred a net loss of $3,774,563 and generated negative operating cash flow of $10,462,332 for the nine-month period ended June 30, 2024[26]. - Loss from operations increased by $3,971,041 or 59% to $10,753,510 for the nine-month period ended June 30, 2024, compared to $6,782,469 for the same period in 2023[183]. Cash and Assets - Cash and cash equivalents as of June 30, 2024, were $10,442,131, an increase from $7,151,800 as of September 30, 2023[8]. - Total assets as of June 30, 2024, were $16,690,091, up from $13,651,577 as of September 30, 2023[9]. - Total liabilities as of June 30, 2024, were $4,455,636, a decrease from $8,779,165 as of September 30, 2023[9]. - The company had cash, cash equivalents, and restricted cash of $11,192,131 at the end of the period, compared to $11,506,235 at the end of June 30, 2023, showing a decrease of approximately 3%[19]. - Cash flows from operating activities showed a net cash used of $10,462,332 for the nine months ended June 30, 2024, compared to $3,537,911 in the same period of 2023, representing a significant increase in cash outflow[19]. Stock and Shareholder Information - The company reported a weighted average of 4,014,261 shares outstanding for the three months ended June 30, 2024, compared to 645,426 shares in the same period of 2023[11]. - The company issued 724,923 common stock and pre-funded warrants in a public offering, netting $10,525,063, which contributed to financing activities[19]. - A reverse stock split of 1-for-20 was executed on April 25, 2024, affecting all share and warrant information retroactively[22]. - The balance of common shares increased to 10,299,385 as of June 30, 2024, up from 645,426 shares at the beginning of the reporting period[14]. - The company received net proceeds of approximately $10.5 million from the Registered Direct Offering (RDO) closed on May 29, 2024, which helped regain compliance with Nasdaq's stockholders' equity requirement[79]. Revenue Sources and Segments - The company has three reportable segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services[48]. - The company’s revenues for the three and nine-month periods ended June 30, 2024 included 28% and 26% from one customer in the MDx Testing Services segment, respectively[45]. - The company recognized $0 and $40,035 of revenue from contract liabilities for the three and nine-month periods ended June 30, 2024, respectively[40]. - The company’s clinical laboratory testing services revenue for the three-month period ended June 30, 2024 was $13,150, a significant decrease from $1,521,315 in the same period of 2023[34]. Research and Development - Research and development expenses increased by $76,908 or 9% to $913,031 for the three-month period ended June 30, 2024, driven by enzyme development costs[164]. - Research and development expenses decreased by $34,131 or 1% to $2,762,040 for the nine-month period ended June 30, 2024, compared to $2,796,171 for the same period in 2023[175]. - The company is focusing on the development and commercialization of its Therapeutic DNA Production Services, with plans to expand its contract development and manufacturing operations for synthetic DNA[128]. Market and Strategic Developments - The company is focused on developing and commercializing technologies for DNA and RNA production and detection, with recent acquisitions aimed at enhancing its capabilities in mRNA therapeutics[21]. - The company launched its Linea IVT platform in July 2023, which combines its Linea DNA IVT templates with Spindle's proprietary RNAP, potentially increasing its mRNA-related total addressable market by approximately 3-5 times[136]. - The company is currently developing its Linea RNAP under an ISO 13485 quality system to increase production scale and reduce unit costs[136]. - The company is monitoring its business strategy and resource allocation to adapt to available opportunities in its various business markets[128]. Compliance and Regulatory Issues - The company received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as the closing bid price was below $1.00 for 30 consecutive business days[113]. - The company plans to implement a reverse stock split to regain compliance with Nasdaq listing requirements, pending shareholder approval[114]. - The FDA's final rule on laboratory developed tests will require compliance with various phases starting May 6, 2025, impacting the company's MDx Testing Services[150]. Risks and Uncertainties - Company highlights risk factors that could materially harm business and financial condition[205]. - Additional uncertainties may adversely affect future results[205]. - The company faces risks related to regulatory approvals and compliance for its Therapeutic DNA Production Services, which are critical to its business strategy[121].

Investors might want to bet on Applied DNA Sciences (APDN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Applied DNA Sciences (APDN) came out with a quarterly loss of $5.31 per share versus the Zacks Consensus Estimate of a loss of $4.60. This compares to loss of $4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -15.43%. A quarter ago, it was expected that this DNA-based security technology company would post a loss of $6.20 per share when it actually produced a loss of $1.80, delivering a surprise of 70.97%.Over the last four q ...

Exhibit 99.1 Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results STONY BROOK, N.Y. – May 10, 2024 - Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. The Company will not host a financial webcast or call for this most recent quarterly reporting ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

The Industrial Products group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Applied DNA Sciences (APDN) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Applied DNA Sciences is a member of our Industrial Products group, which includes 227 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in o ...

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2024 Results Conference Call February 8, 2024 4:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - Chief Financial Officer Dr. James Hayward - Chairman, President and CEO Clay Shorrock - Chief Legal Officer and Head of Business Development Judy Murrah - Chief Operating Officer Conference Call Participants Jason McCarthy - Maxim Group Dipesh Patel - H.C. Wainwright Jeffrey Bernstein - Silverberg Bernstein Capital Operator Good day and welcome to ...

Applied DNA Sciences (APDN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 70.97%. A quarter ago, it was expected that this DNA-based security technology company would post a loss of $0.27 per share when it actually produced a loss of $0.26, delivering a surprise of 3.70%.Over the last four ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Conference Call December 7, 2023 4:30 PM ET Company Participants Sanjay Hurry - Head of IR Beth Jantzen - CFO James Hayward - Chairman, President and CEO Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Jason McCarthy - Maxim Group Yi Chen - H.C. Wainwright Operator Good Day and welcome to the Applied DNA Sciences Fiscal Fourth Quarter 2023 Financial Results Conference Call. [Operator Instructions] Ple ...